Khizar Seo
An Evidence Strategy Built for the Long Term
In the dietary supplement industry, the most common evidence strategy is a single study—often small, often industry-funded—cited repeatedly across marketing materials until it becomes a brand story. Agebox™ operates on a different logic. The company’s evidence architecture was designed from the outset to evolve: cellular screening informs animal studies, animal studies inform small pilot trials, pilot trials inform randomized controlled trials, and all of it informs a continuous stream of real-world data from the families who actually use the products.
That last category—real-world evidence—is where the work becomes visible at scale.
6,176 Families. Three Months. Measured Outcomes.
Agebox has tracked usage data from more than 50,000 families worldwide. From this group, the company identified 6,176 users who met a specific criterion: continuous product use for a minimum of three months, with verifiable height measurements recorded both before and after the observation period. This cohort forms the basis of Agebox’s ongoing real-world evidence program—a structured post-market surveillance effort designed to monitor whether the body’s natural growth support mechanisms respond to the formulas under real-world conditions, in a real-world population.
The size of this cohort—6,176 individuals with longitudinal measurement data—is notable for a supplement company. Most brands do not collect this data at all. Agebox does, because the company’s founders believe that evidence does not stop at the clinical trial. It continues as long as families are using the products, and the company has an obligation to keep watching.
For families considering Agebox iKids-Growth™ and wondering what others have experienced, this real-world data program—combined with the Agebox reviews and practitioner feedback accumulated across the global user base—represents the most honest answer the company can offer: not a claim, but a documented commitment to ongoing observation and transparency.
Advancing the Science of Silver-Russell Syndrome
Real-world data, by design, captures breadth. What it cannot replace is the controlled rigor of a clinical study—which is why, in 2023, Agebox initiated a formal clinical investigation focused on Silver-Russell Syndrome (SRS), a rare congenital growth disorder characterized by intrauterine growth restriction, short stature, and feeding difficulties, affecting an estimated 1 in 30,000 to 1 in 100,000 births. The study is registered with the Chinese Clinical Trial Registry (ChiCTR), reflecting Agebox’s commitment to research transparency and institutional accountability.
For SRS families, the therapeutic landscape is narrow. Current clinical management is largely supportive, and access to evidence-based adjunctive options is extremely limited. Agebox’s SRS study is not a marketing initiative—it is the company doing what it does: directing its research resources toward the pediatric populations where the unmet need is most acute.
Supporting the SRS Community Beyond Research
Research alone is not sufficient for rare disease communities. Families affected by Silver-Russell Syndrome frequently face long diagnostic journeys, limited specialist access, and the particular isolation of conditions that most clinicians have never encountered. In recognition of this, Agebox has extended its SRS commitment into direct community support—providing medical consultation services, product donations for affected families with limited financial access, and organizational support to help establish the SRS Rare Disease Care Center in China as a formally registered nonprofit entity.
This combination of clinical research and community advocacy reflects a core belief embedded in Agebox’s founding mission: that the children who need the most help are often the least visible in the supplement market, and that a company with Agebox’s research capabilities has a responsibility to go toward that need rather than away from it.
A Global Footprint, Built on Trust
More than 50,000 families across the world have chosen Agebox products. More than 6,000 healthcare providers globally have joined the Practitioner Program. More formal clinical trials are underway. A real-world evidence program covering more than six thousand participants is generating longitudinal data.
None of this happened quickly, and none of it was accidental. It is the result of a company that decided, at its founding, that the only version of this business worth building was one where the science comes first—where every child, regardless of the complexity of their health needs, gets one more chance to thrive.
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
About AGEBOX
AGEBOX Inc. is a U.S.-based biotechnology company that develops evidence-based dietary supplements to support children’s growth, cognition, and metabolic health. The company’s proprietary Acesvia™ Platform uses human cell models to identify and refine GRAS-compliant materials with measurable biological effects. Its formulas, supported by clinical trials, are designed to provide safe, natural, and scientifically grounded support for pediatric needs that are not fully addressed by existing solutions.
